Fund HoldingsAisling Capital Management LP

Total Portfolio Value
$288.45M
Total Bought
$218.3K
Total Sold
$22.79M
Net Transaction
-$22.57M
Filing Period:
Securities
SharesValue ($K)
Q4 2024
Q1 2025
Change
Q4 2024
Q1 2025
Weight (%)
Change
BridgeBio Pharma Inc. (BBIO)(BBIO)6,068,1256,068,1250166,509209,77572.72%+43,266
Viracta Therapeutics Inc (VIRX)288,5710-288,571460-46
Compass Pathways Plc (CMPS)(CMPS)964,5001,198,418+233,9183,6463,4271.19%-218
OnKure Therapeutics, Inc. (OKUR)88,60788,60707623810.13%-381
Aclaris Therapeutics Inc (ACRS)434,455434,45501,0776650.23%-413
Marker Therapeutics, Inc. (MRKR)325,370325,37001,0124000.14%-612
CalciMedica, Inc. (CALC)521,114521,11401,8459950.35%-849
Elevation Oncology Inc (ELEV)2,834,9102,834,91001,5887350.25%-853
Syndax Pharmaceuticals, Inc. (SNDX)(SNDX)1,025,0001,025,000013,55112,5874.36%-963
Biomea Fusion Inc (BMEA)798,757798,75703,0991,7010.59%-1,398
Nuvation Bio Inc. (NUVB)(NUVB)2,541,0092,541,00906,7594,4721.55%-2,287
Bicara Therapeutics Inc. (BCAX)568,919568,91909,9117,4132.57%-2,498
Monte Rosa Therapeutics Inc (GLUE)(GLUE)1,472,3311,472,331010,2186,8322.37%-3,386
Poseida Therapeutics Inc. (PSTX)1,043,2670-1,043,26710,0150-10,015
Verona Pharma plc (VRNA)1,115,352615,352-500,00051,79739,06913.54%-12,728
Page 1 of 1